Search | Clinical Trials Finder

Conditions: Cigarette, Smoking Behaviors, Cigarette Smoking Behavior
Interventions: Mentholated cigarette sampling, Hypothetical Policy Scenarios, Subjective value assessment; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 21 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Dental Caries
Interventions: 0.425 % w/w phytate,1150ppm F, 0.85 % w/w phytate,1150ppm F, 0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F, 0 ppm F, 1150ppm F, 0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Healthy
Interventions: Listerine Experimental Mouthwash, Colgate Cavity Protection Toothpaste, Listerine Total Care Zero, Listerine Cool Mint Zero; Drug · Other
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Dry Mouth
Interventions: Marketed Dry Mouth Rinse, Water control, Experimental Dry Mouth Rinse; Device · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Paclitaxel, Irinotecan, Pembrolizumab, MK-4830, Lenvatinib, Sacituzumab tirumotecan, Antihistamine, H2 Receptor Antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid Mouthwash (dexamethasone or equivalent), Supportive care measures; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 5
States / cities: Tucson, Arizona • Los Angeles, California • East Syracuse, New York + 2 more

Conditions: Malignant Neoplasm
Interventions: MK-1084, Pembrolizumab, Cetuximab, Sacituzumab tirumotecan (sac-TMT), Rescue medication; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Clermont, Florida • Fargo, North Dakota • Sioux Falls, South Dakota

Conditions: Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Interventions: Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan, Rescue Medications, HER3-DXd; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Tucson, Arizona • Los Angeles, California • Louisville, Kentucky + 5 more

Conditions: Advanced Breast Cancer
Interventions: Dexamethasone based mouthwash, Everolimus, Exemestane; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Fayetteville, Arkansas • Anaheim, California • Los Angeles, California + 17 more

Conditions: Microbiome, Cytokines, Plaque, Gingivitis, Gingival Bleeding
Interventions: Distilled Water, Marketed Comparator 1, Marketed Comparator 2, Prototype Rinse 1, Prototype Rinse 2; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Dentin Sensitivity
Interventions: Mouth Rinse, Fluoride Toothpaste, Potassium Nitrate Toothpaste; Device · Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Dentin Sensitivity
Interventions: Experimental Oral Rinse 1, Experimental Oral Rinse 2, Placebo Oral Rinse, Fluoride toothpaste; Device · Other · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Dentin Sensitivity
Interventions: Experimental Oral Rinse 1, Experimental Oral Rinse 2, Placebo Oral Rinse, Standard fluoride toothpaste; Device · Other · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Lung Neoplasm Malignant
Interventions: Pembrolizumab (neoadjuvant), Cisplatin, Gemcitabine, Pemetrexed, Sacituzumab tirumotecan, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Carboplatin, Pembrolizumab (adjuvant), Paclitaxel, Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 9
States / cities: Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more

Conditions: Dry Mouth
Interventions: dry mouth rinse, Water Control; Device · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Xerostomia
Interventions: Biotene mouthwash, Mineral Water; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Oral Health
Interventions: Prototype 1, Prototype 2, Marketed Comparator; Other
Lead sponsor: Kenvue Brands LLC; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Dental Plaque
Interventions: 19416-154-1, W002194-0221P; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Dental Plaque, Gingivitis
Interventions: Crest Cavity Protection Toothpaste, Experimental Mouthwash; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Dentin Sensitivity
Interventions: Mouthwash, Potassium nitrate toothpaste, Sodium fluoride toothpaste; Device · Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes Type 2, Periodontal Disease, Caries
Interventions: Diabetes Oral Health Program, Stannous Fluoride Dentifrice, Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash; Behavioral · Drug
Lead sponsor: Colgate Palmolive; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Long Island City, New York

Conditions: Dentin Sensitivity
Interventions: Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0), Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5), Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 ); Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 221 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Oral Manifestations
Interventions: Potassium Oxalate without Fluoride, Potassium Oxalate with Fluoride, Active Comparator PO-116-A; Device
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Fort Wayne, Indiana

Conditions: Stomatitis
Interventions: Etanercept, Placebo; Drug
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 16 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Greenville, South Carolina

Conditions: Dental Plaque, Dental Caries
Interventions: Bromelain, Powdered sugar; Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 10 Years to 25 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

An Experimental Evaluation of Menthol-Flavored Tobacco Accessories

Efficacy of Three Toothpastes Using an in Situ Caries Model

A Two-Week Study of an Anticavity Low pH Mouthwash

A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Comparison of the Effects of Oral Hygiene Regimens on Clinical, Immunomodulatory, and Microbial Outcomes and Oral Tolerance in People With Gingivitis

A Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity

A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.

Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Improvement of Dry Mouth Sufferers After Using an Experimental Dry Mouth Rinse Compared to a Water Control

Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms

Determination of the Oral Irritation Potential of Two Alcohol-Free Rinses

A Four-Week Study to Measure the Effectiveness of an Experimental Mouthwash Used After Teeth Cleaning

A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

A Study of the Relief of Tooth Sensitivity of an Experimental Mouthrinse Device

Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes

A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.

Oral Irritation Study of Two Experimental Mouthrinses

Evaluation of Efficacy and Mechanisms of an Antiinflammatory Intervention for Chemotherapy Related Mucosal Injury

Evaluation of Oral Plaque Removal Utilizing an Adjunct Enzyme Pre-rinse